CHNA
Loncar China BioPharma ETF
CHNA
CHNA
Delisted
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $90K invested in Loncar China BioPharma ETF in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$18K |
| 2 |
Citigroup
New York
|
+$10K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$347K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
1
Morgan Stanley
New York
| $50K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $18K | +$18K | +732 | New |
|
|
AG
3
Advisor Group
Phoenix,
Arizona
| $12K | – | – | – |
|
|
4
Citigroup
New York
| $10K | +$10K | +390 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$347K | -16,162 | Closed |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| – | -$1K | -44 | Closed |
|